Biomarker discovery and analysis company Metabolon has expanded its capabilities to discover new biomarkers.

The Morrisville company has unveiled new software technology that can survey biological samples to see if they contain the more than 4,000 known metabolites within in its chemical library. It’s a capability that Metabolon gained through its acquisition of Lipomics Technologies last year. Lipomics now operates as a division within Metabolon.

The new software can be used in an array of life science applications to discover biomarkers and study the effects of drugs or nutrients on metabolism. TrueVision can also yield insight into disease biology, particularly metabolic diseases.

Metabolism in general, and lipid metabolism in particular, are thought to play an important role in the development of cancer, inflammatory and central nervous system disorders. Metabolon says a comprehensive offering makes this technology especially suited for research in these therapeutic areas.